Novo Nordisk A/S (NYSE:NVO) shares sold by Kathmere Capital Management LLC

Kathmere Capital Management LLC lessened its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 4.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. & Exchange Commission. The institutional investor owned 19,910 shares of the company’s stock after selling 854 shares during the period. Kathmere Capital Management LLC’s holdings in Novo Nordisk A/S were worth $2,842,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. Advisor OS LLC boosted its holdings in shares of Novo Nordisk A/S by 0.6% during the second quarter. Advisor OS LLC now owns 13,972 shares of the company’s stock valued at $1,994,000 after acquiring an additional 82 shares during the last quarter. Cascade Financial Partners LLC boosted its position in shares of Novo Nordisk A/S by 2.3% in the second quarter. Cascade Financial Partners LLC now owns 3,801 shares of the company’s stock worth $543,000 after purchasing an additional 84 shares during the period. Cravens & Co Advisors LLC boosted its holdings in shares of Novo Nordisk A/S by 1.0% in the first quarter. Cravens & Co Advisors LLC now owns 8,250 shares of the company’s stock valued at $1,059,000 after purchasing an additional 85 shares during the period. AA Financial Advisors LLC lifted its position in Novo Nordisk A/S by 3.2% during the 2nd quarter. AA Financial Advisors LLC now owns 2,805 shares of the company’s stock worth $400,000 after purchasing an additional 86 shares. shares in the last quarter. Finally, Steel Grove Capital Advisors LLC boosted its holdings in Novo Nordisk A/S by 2.3% in the second quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company’s stock worth $541,000 after acquiring an additional 86 shares during the period. 11.54% of the shares are currently held by hedge funds and other institutional investors.

Novo Nordisk A/S stock down 2.8%

Shares of Novo Nordisk A/S opened at $120.76 on Friday. The company has a 50-day moving average price of $131.97 and a 200-day moving average price of $133.00. Novo Nordisk A/S has a fifty-two week low of $86.96 and a fifty-two week high of $148.15. The firm has a market cap of $541.91 billion, a P/E ratio of 41.64, a P/E/G ratio of 1.35 and a beta of 0.42. The company has a quick ratio of 0.75, a current ratio of 0.94, and a debt-to-equity ratio of 0.46.

Novo Nordisk A/S (NYSE:NVO – Get Free Report ) last posted its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. The firm had revenue of $9.82 billion during the quarter, compared to the consensus estimate of $9.91 billion. On average, sell-side analysts forecast that Novo Nordisk A/S will post 3.11 earnings per share for the current fiscal year.

Novo Nordisk A/S cuts dividends

The firm also recently announced a semiannual dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 16th were given a dividend of $0.5126 per share. The ex-dividend date of this dividend was Friday, August 16. This represents a dividend yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 24.83%.

The Wall Street analyst weighs in

NVO has been the subject of several analyst reports. BMO Capital Markets dropped their price objective on shares of Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th . Argus raised their target price on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, June 10th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Monday, September 16th. Finally, StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 18th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Novo Nordisk A/S presently has an average rating of “Buy” and an average target price of $145.17, according to MarketBeat data.

Read our latest research report on Novo Nordisk A/S

Profile of Novo Nordisk A/S

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, is engaged in the research and development, manufacturing and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America and internationally. It operates in two segments, diabetes and obesity care and rare diseases.

Read more

Get news and reviews for Novo Nordisk A/S Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Novo Nordisk A/S and related companies with MarketBeat.com’s FREE daily email newsletter.